LIGAND PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional paid in capital · Accumulated other comprehensive income · Retained earnings · Total stockholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 19,774 | $20 | $400,649 | $8,455 | $608,088 | $1,017,212 |
| Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes | 255 | — | (14,076) | — | — | (14,076) |
| Share-based compensation | — | — | 10,596 | — | — | 10,596 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | (732) | — | (732) |
| Foreign currency translation adjustment, net of tax | — | — | — | (2,333) | — | (2,333) |
| Net loss | — | — | — | — | (13,345) | (13,345) |
| Balance at March 31, 2026 | 20,029 | $20 | $397,169 | $5,390 | $594,743 | $997,322 |
| Common Stock · Additional paid in capital · Accumulated other comprehensive loss · Retained earnings · Total stockholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 19,106 | $20 | $337,377 | $(5,942) | $498,984 | $830,439 |
| ASU 2025-07 adoption: impact as of January 1, 2025 | — | — | — | — | (438) | $(438) |
| Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes | 170 | — | (4,669) | — | — | (4,669) |
| Share-based compensation | — | — | 7,836 | — | — | 7,836 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | (22) | — | (22) |
| Foreign currency translation adjustment, net of tax | — | — | — | 4,401 | — | 4,401 |
| Net loss (as reported) | — | — | — | — | (42,451) | (42,451) |
| ASU 2025-07 adoption: impact on net loss | — | — | — | — | 498 | 498 |
| Balance at March 31, 2025* | 19,276 | $20 | $340,544 | $(1,563) | $456,593 | $795,594 |
*Interim equity balances reflect the impact of ASU 2025-07 adoption in Q3 2025 effective January 1, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.